Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;51(3):134-46.
doi: 10.1016/j.resinv.2013.02.005. Epub 2013 Apr 30.

Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension

Affiliations
Free article
Review

Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension

Nobuhiro Tanabe et al. Respir Investig. 2013 Sep.
Free article

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by non-resolving thromboembolisms of the pulmonary arteries. In Japan, in contrast to Western countries, CTEPH is more prevalent in women. A Japanese multicenter study reported that a form of CTEPH unrelated to deep vein thrombosis is associated with HLA-B⁎5201, suggesting that this form of CTEPH may be associated with vasculopathy. CTEPH can be cured by pulmonary endarterectomy, provided that the thrombi are surgically accessible; thus, early diagnosis is important, and all patients with exertional dyspnea should be evaluated for pulmonary hypertension. Ventilation/perfusion scans provide an excellent non-invasive means to distinguish CTEPH from pulmonary arterial hypertension. Similarly, computed tomographic pulmonary angiograms allow for the detection of thrombi and evaluation of pulmonary hemodynamics in a minimally invasive manner. Importantly, the absence of subpleural perfusion on pulmonary angiograms can suggest the presence of small vessel disease. Small vessel disease might be involved in the pathogenesis of CTEPH, and its detection is essential in preventing operative death. Although no modern therapies for pulmonary arterial hypertension have been approved for treatment of CTEPH, a recent randomized control trial of riociguat in patients with CTEPH demonstrated that riociguat significantly improved 6-min walking distance. Further investigations into treatments that target endothelial dysfunction and hyperproliferative CTEPH cells are needed. Recently, balloon pulmonary angioplasty has emerged as a promising treatment modality in Japan. A specialized medical team, including at least one expert surgeon, should make decisions regarding patients' candidacy for pulmonary endarterectomy and/or balloon pulmonary angioplasty.

Keywords: 6-min walk distance; BPA; Balloon pulmonary angioplasty; CT; CT pulmonary angiography; CTEPH; CTPA; Chronic thromboembolic pulmonary hypertension; DVT; MD; MHLW; MR; Ministry of Health, Labor and Welfare; PAH; PE; PEA; PH; PVR; Ppa; Pulmonary endarterectomy; RCT; SPECT; V/Q; balloon pulmonary angioplasty; chronic thromboembolic pulmonary hypertension; computed tomographic; computed tomographic pulmonary angiography; deep vein thrombosis; magnetic resonance; pulmonary arterial hypertension; pulmonary arterial pressure; pulmonary embolism; pulmonary endarterectomy; pulmonary hypertension; pulmonary vascular resistance; randomized controlled trial; single-photon emission computed tomography; ventilation/perfusion.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources